Clinical Trials Arena on MSN
CVRx’s stock up as heart failure device to be trialled in expanded patient group
The device gained approval in the US in 2019 and received CE marking for use in the EU in 2014.
CVRx, Inc. a developer of neuromodulation solutions for patients with cardiovascular diseases, announced initiation of the ...
CVRx, Inc. initiates landmark BENEFIT-HF trial with FDA-approved Barostim device, aiming to expand heart failure patient ...
The vascular surgery team at UCSF Health recently became the first among University of California medical centers to implant a Barostim device to treat heart failure. The team implanted the device in ...
Chuck Moon, a congestive heart failure patient, experienced significant improvement in his quality of life after receiving a Barostim device implant. The Barostim device is a new technology that acts ...
TUCSON, Ariz. (KVOA) - Carondelet St. Mary's Hospital has successfully completed its first implantation of the Barostim™ Baroreflex Activation Therapy device, marking a significant advancement in the ...
CMS proposed to retain Barostim implant procedure in APC 1580 with a $45,000 outpatient payment, enhancing reimbursement for heart failure treatments. CVRx, Inc. announced that the Centers for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results